Affinage

TGFBR2

TGF-beta receptor type-2 · UniProt P37173

Length
567 aa
Mass
64.6 kDa
Annotated
2026-06-10
100 papers in source corpus 43 papers cited in narrative 43 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 8/8 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

TGFBR2 is the type II transmembrane serine/threonine kinase receptor for the TGFβ family that, upon ligand binding, drives canonical SMAD2/3 phosphorylation and a parallel non-canonical ERK/p38 MAPK output, governing tissue homeostasis across the cardiovascular, skeletal, craniofacial, neural, and immune systems (PMID:24401272, PMID:20628007). The relative balance of these two arms is functionally decisive: heterozygous TGFBR2 mutations cause connective-tissue disorders (Loeys-Dietz syndrome and Marfan syndrome type 2) in which mutant alleles fail to support TGFβ signaling in vitro yet paradoxically yield increased phospho-SMAD2 and collagen/CTGF in patient tissue, and the degree of impaired SMAD versus ERK signaling tracks with phenotypic severity (PMID:15731757, PMID:15235604, PMID:21098638). In smooth muscle, TGFBR2 is required for contractile differentiation and aortic wall integrity, and its postnatal loss lowers SMAD while raising MAPK signaling to produce thoracic aortic dilation and dissection (PMID:24401272, PMID:20628007). During development TGFBR2 controls programmed cell death and Irf6 expression in palatal epithelium, sclerotome boundary maintenance, osteoblast proliferation and differentiation, and tooth root formation (PMID:16780827, PMID:16824508, PMID:19699732, PMID:28043895). In the nervous and immune systems, neural TGFBR2 shapes a pro-angiogenic secretome, and NG2-glia-derived TGFβ2 acts through microglial TGFBR2 to suppress neuroinflammation via CX3CR1 (PMID:24990151, PMID:31727112). In cancer, TGFBR2 is a tumor suppressor inactivated by coding-microsatellite frameshift mutation in mismatch-repair-deficient colorectal cancer, where its loss deregulates cdk4-driven proliferation and cooperates with Apc/Kras to drive metastasis; loss of the Smad-independent ERK1/2 arm downstream of TGFBR2 derepresses SOX2 to promote lung squamous carcinoma (PMID:16108056, PMID:29282223, PMID:31209059). TGFBR2 surface abundance is set by competing trafficking and degradation inputs—endosomal recycling promoted by an ITGB5/SNX17 scaffold versus PIEZO1/Rab3C-driven endocytosis-autophagy and NRP1-mediated membrane retention—and by ubiquitin-dependent turnover balanced by the E3 ligase HUWE1 and the deubiquitinase USP33 (PMID:38729557, PMID:39585648, PMID:37220183, PMID:33405091, PMID:37322017). Its transcription is directly activated by GABPA, SOX4/SMARCA4, and YAP-1/TEAD and repressed by EZH2, MYOCD/PRMT5, and a super-enhancer, while multiple miRNAs including miR-21, miR-145, miR-93, and miR-520e silence it through 3'-UTR binding, several within TGFβ-driven feedback loops (PMID:35549739, PMID:33837205, PMID:28472799, PMID:29699590, PMID:33995678, PMID:31730895, PMID:24037531, PMID:25323858, PMID:30475986).

Mechanistic history

Synthesis pass · year-by-year structured walk · 12 steps
  1. 2004 High

    Establishing that TGFBR2 loss-of-function causes heritable connective-tissue disease defined the receptor as essential for extracellular matrix homeostasis in humans.

    Evidence Breakpoint mapping and sequencing of TGFBR2 with TGFβ signaling/ECM functional assays in Marfan syndrome type 2 families

    PMID:15235604

    Open questions at the time
    • Did not resolve which downstream arm (SMAD vs MAPK) drives ECM dysregulation
    • Cellular site of action not pinpointed
  2. 2005 High

    The paradox that mutant alleles fail to signal in vitro yet show elevated phospho-SMAD2 and collagen in patient tissue reframed disease as dysregulated rather than simply absent TGFβ signaling.

    Evidence Patient-derived signaling kinetics and tissue immunostaining for p-Smad2/collagen/CTGF across Loeys-Dietz families

    PMID:15731757

    Open questions at the time
    • Mechanism reconciling in vitro loss with in vivo gain not established
    • Did not identify the compensatory pathway raising SMAD output
  3. 2010 High

    Allelic series quantification linked the SMAD-versus-ERK signaling balance of individual mutations to clinical severity, explaining genotype-phenotype variation.

    Evidence Quantitative cell-based assays of stability, internalization, Smad phosphorylation, ERK, and transcription across nine patient mutations; patient SMC/fibroblast differentiation assays

    PMID:20628007 PMID:21098638

    Open questions at the time
    • Causal direction between ERK gain and disease not proven in vivo
    • Tissue-specific signaling thresholds undefined
  4. 2014 High

    Conditional smooth-muscle knockout established that postnatal TGFBR2 maintains aortic wall integrity, with disease driven by decreased SMAD and increased MAPK signaling and rescuable by rapamycin.

    Evidence Smooth-muscle Cre/lox Tgfbr2 knockout with Smad/MAPK Westerns, histology, and rapamycin treatment in mice

    PMID:24401272

    Open questions at the time
    • Molecular trigger of MAPK upregulation upon TGFBR2 loss unresolved
    • Adventitial paracrine factors not fully identified
  5. 2009 High

    Tissue-specific conditional knockouts mapped distinct developmental requirements for TGFBR2 in palate, sclerotome, skull, bone, and tooth, separating proliferation from differentiation roles.

    Evidence Multiple Cre/lox conditional Tgfbr2 knockouts (palatal epithelium, Col2a, Prx1, Osx, odontoblast) with marker analysis, BrdU, TUNEL, and ex vivo deletion

    PMID:16780827 PMID:16824508 PMID:19699732 PMID:23933490 PMID:25818583 PMID:28043895

    Open questions at the time
    • Downstream effectors (e.g., Irf6, Runx2) placement only partially mechanistic
    • Ligand source in each tissue not always defined
  6. 2008 High

    Microsatellite frameshift inactivation of TGFBR2 in mismatch-repair-deficient cancer, with mutation rate set by the specific MMR background, identified TGFBR2 as a tumor suppressor target and quantified its vulnerability.

    Evidence TGFBR2 reconstitution in MSI HCT116 cells with cdk4 readouts; EGFP frameshift reporters across MLH1/MSH6-deficient backgrounds

    PMID:16108056 PMID:18941508

    Open questions at the time
    • Did not address metastatic cooperation
    • Downstream secretory/microbiota consequences not yet examined
  7. 2019 High

    Genetic epistasis defined TGFBR2 as a metastasis suppressor and revealed a Smad-independent ERK1/2 arm restraining SOX2-driven squamous carcinoma.

    Evidence Combinatorial Apc/Kras/Tgfbr2/Trp53 intestinal knockouts with organoid metastasis assays; Kras×Tgfbr2 vs Kras×Smad4 lung models with ERK inhibition

    PMID:29282223 PMID:31209059

    Open questions at the time
    • How TGFBR2 maintains ERK tone to suppress SOX2 mechanistically incomplete
    • Relative contribution of SMAD vs ERK loss to metastasis not isolated
  8. 2019 Medium

    TGFBR2 status was shown to reprogram secreted exosome/EV cargo, glycosylation of Notch1 via LFNG, and cytokine secretion, extending its tumor-suppressor role to the secretome.

    Evidence Doxycycline-inducible TGFBR2 reconstitution in HCT116 with exosome proteomics, small-RNA sequencing, metabolic GlcNAc labeling, and Luminex cytokine profiling

    PMID:27156840 PMID:28376875 PMID:31432155

    Open questions at the time
    • Functional consequence of altered exosome cargo on tumor progression not established in vivo
    • Single isogenic model
  9. 2019 High

    Beyond cell-autonomous signaling, TGFBR2 was shown to coordinate paracrine programs: neural TGFBR2 shapes a pro-angiogenic secretome and microglial TGFBR2 enforces immune homeostasis.

    Evidence Foxg1-Cre Tgfbr2 knockout with conditioned-medium HUVEC rescue; NG2-glia ablation and microglial TGFBR2 gain/loss in MPTP neuroinflammation model

    PMID:24990151 PMID:31727112

    Open questions at the time
    • Transcriptional control of the secretome by TGFBR2 not detailed
    • CX3CR1 coupling mechanism downstream of TGFBR2 unresolved
  10. 2024 Medium

    Receptor surface abundance was established as an actively regulated node, with recycling, endocytosis/autophagy, membrane retention, and ubiquitin turnover each tuning TGFβ output.

    Evidence ITGB5/SNX17/TGFBR2 Co-IP and recycling assays; PIEZO1/Rab3C conditional KO and Yoda1 rescue in Marfan mice; NRP1 Co-IP and endothelial KO; HUWE1 ubiquitination and USP33 deubiquitination assays

    PMID:33405091 PMID:37220183 PMID:37322017 PMID:38729557 PMID:39585648

    Open questions at the time
    • Hierarchy/competition among trafficking regulators not integrated
    • Several mechanisms rest on single-lab Co-IP or ubiquitination assays
  11. 2022 Medium

    Transcriptional and post-transcriptional control of TGFBR2 was mapped to direct activators, repressive epigenetic complexes, and miRNA feedback loops, defining how receptor dosage is set.

    Evidence ChIP for GABPA, SOX4/SMARCA4, YAP-1/TEAD activators; EZH2/H3K27me3, MYOCD/PRMT5, and super-enhancer repression; 3'-UTR reporters for miR-21/AR, miR-145, miR-93, miR-520e feedback circuits

    PMID:24037531 PMID:25323858 PMID:28472799 PMID:29699590 PMID:30475986 PMID:31730895 PMID:33296708 PMID:33837205 PMID:33995678 PMID:35549739

    Open questions at the time
    • Context-specific dominance among these regulators not resolved
    • Many circuits validated in single cancer cell systems
  12. 2021 High

    Therapeutic engineering of TGFBR2 signaling was demonstrated by knocking it out in tumor-infiltrating lymphocytes to escape TGFβ immunosuppression.

    Evidence CRISPR/Cas9 TGFBR2 knockout in primary patient TILs with p-SMAD, cytokine, and cytotoxicity readouts

    PMID:35882447

    Open questions at the time
    • Durability and in vivo antitumor efficacy not addressed
    • Effect limited to SMAD-axis readouts

Open questions

Synthesis pass · forward-looking unresolved questions
  • How the SMAD-versus-MAPK signaling balance is set in a tissue-specific manner—and whether the trafficking/degradation and transcriptional regulators converge to control this balance—remains the central unresolved question.
  • No unified model linking receptor dosage control to the SMAD/ERK output ratio
  • Mechanism converting reduced TGFBR2 to increased MAPK/SMAD signaling in vivo undefined
  • Structural basis of mutation-specific signaling bias not determined

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0060089 molecular transducer activity 3 GO:0140096 catalytic activity, acting on a protein 3 GO:0016740 transferase activity 1
Localization
GO:0005886 plasma membrane 3 GO:0005768 endosome 2
Pathway
R-HSA-1643685 Disease 5 R-HSA-1266738 Developmental Biology 4 R-HSA-9609507 Protein localization 4 R-HSA-162582 Signal Transduction 3 R-HSA-168256 Immune System 3
Partners
HUWE1ITGB5NRP1PDGFRPIEZO1SNX17USP33

Evidence

Reading pass · 43 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2005 Heterozygous mutations in TGFBR2 (or TGFBR1) cause a syndrome of cardiovascular, craniofacial, neurocognitive and skeletal abnormalities (Loeys-Dietz syndrome); despite mutant alleles failing to support TGFβ signal propagation in vitro, patient-derived tissues showed increased nuclear phospho-Smad2 and elevated collagen/CTGF expression, indicating paradoxically increased TGFβ signaling in vivo. Patient-derived cell culture assays of acute TGFβ signaling kinetics; immunostaining of patient tissues for p-Smad2, collagen, and CTGF; genetic mutation analysis Nature genetics High 15731757
2004 Heterozygous mutations in TGFBR2 cause Marfan syndrome type 2 (MFS2); identified mutations lead to loss of TGFβ signaling activity on extracellular matrix formation. Chromosomal breakpoint mapping, DNA sequencing of TGFBR2, functional assessment of TGFβ signaling activity and ECM formation in mutation carriers Nature genetics High 15235604
2014 Postnatal conditional inactivation of Tgfbr2 in smooth muscle cells causes thoracic aortic thickening, dilation, and dissection; loss of TGFBR2 decreases canonical Smad signaling but unexpectedly increases MAPK signaling, and aortic disease results from perturbed contractile apparatus in medial cells and paracrine growth factor production by adventitial cells; treatment with rapamycin prevents dissection. Smooth-muscle-specific Cre/lox conditional knockout in mice; TGFβ serologic neutralization; Western blot for Smad and MAPK signaling; rapamycin treatment; aortic histology The Journal of clinical investigation High 24401272
2007 Conditional endothelial deletion of Tgfbr2 (or Alk5) in mice does not affect vessel morphogenesis and does not produce HHT-like vascular malformations, indicating that neither ALK5 nor TGFBR2 is required for ALK1 signaling pertinent to HHT2 pathogenesis. Conditional endothelial-specific Cre knockout of Alk1, Alk5, or Tgfbr2 in mice; vascular phenotype analysis; Alk5 inhibitor in zebrafish Blood High 17911384
2010 Heterozygous TGFBR2 mutations in patient-derived aortic smooth muscle cells decrease expression of SMC contractile proteins and impair TGFβ1-induced upregulation of contractile genes; patient-derived fibroblasts also fail to differentiate into mature myofibroblasts upon TGFβ1 stimulation, establishing that TGFBR2 mutations impair SMC contractile differentiation. Explanted patient aortic SMCs and fibroblasts; TGFβ1 stimulation assays; Western blot and immunostaining for contractile proteins in patient vs. control aortas Cardiovascular research High 20628007
2010 Quantitative analysis of nine TGFBR2 patient mutations showed differing effects on protein stability, internalization, Smad phosphorylation, ERK signaling, and transcriptional activity; mutations associated with LDS and MFS2 showed dominant-negative effects; the R460C TAAD-associated mutation retained residual Smad phosphorylation, suggesting that the balance between defective Smad vs. ERK signaling determines phenotypic severity. Quantitative cell-based assays for TGFBR2 protein expression, turnover (internalization), Smad phosphorylation, ERK activation, and transcriptional reporter activity for nine patient mutations Journal of cell science High 21098638
2006 Cell-autonomous ablation of Tgfbr2 specifically in palatal epithelial cells causes soft palate cleft; mutant MEE cells fail to undergo programmed cell death and instead continue to proliferate and form cysts/epithelial bridges; Irf6 expression is downregulated in Tgfbr2-mutant MEE cells, placing Irf6 downstream of TGFBR2 in palatal epithelial fate determination. Cre/lox conditional knockout of Tgfbr2 in palatal epithelial cells; genetic lineage labeling of MEE; immunostaining for Irf6, K14; histological analysis Developmental biology High 16780827
2006 Deletion of Tgfbr2 in Col2a-expressing cells disrupts maintenance of boundaries in the axial skeleton; loss of Tgfbr2 expands Pax1/Pax9 expression domains across sclerotome segments and reduces Fibromodulin (intervertebral disc marker) expression, demonstrating that TGFBR2 signaling maintains sclerotome segmental boundaries. Col2a-Cre conditional knockout of Tgfbr2 in mice; in situ hybridization and immunostaining for Pax1, Pax9, Msx1, Fmod; histological analysis with PNA staining Developmental biology High 16824508
2009 Conditional loss of Tgfbr2 in Prx1Cre-expressing skull mesenchyme causes open skull defects due to reduced mesenchymal cell proliferation and impaired osteoblast differentiation; in isolated Tgfbr2-deleted osteoprogenitor cultures, mRNA levels of Runx2, Osterix, Dlx5, and Msx2 are downregulated, demonstrating that Tgfbr2 regulates osteoblast differentiation independently of proliferation. Prx1Cre conditional KO; BrdU proliferation assay; TUNEL apoptosis; immunofluorescence for Runx2/Osterix; Adeno-Cre deletion in cultured osteoprogenitors; RT-PCR Developmental biology High 19699732
2013 Deletion of Tgfbr2 in odontoblast/bone mesenchyme (Osx-Cre) disrupts molar root elongation and HERS formation; odontoblast organization and Dspp expression are reduced, while Dmp1 increases; Tgfbr2 in dental mesenchyme indirectly regulates HERS maintenance. Osx-Cre conditional KO of Tgfbr2; microCT; immunostaining for K14, Dspp, Dmp1, Nfic; histological analysis Developmental biology High 23933490
2013 Tgfbr2 mutant palatal mesenchymal cells (Tgfbr2fl/fl;Wnt1-Cre) spontaneously accumulate lipid droplets due to reduced lipolysis; these cells fail to respond to Sonic Hedgehog-driven proliferation; inhibition of p38 MAPK or telmisartan treatment restores lipid metabolism and cell proliferation, rescuing cleft palate in vivo. Cranial neural crest-specific Tgfbr2 conditional KO; lipid droplet staining; lipolysis assay; p38 MAPK inhibitor treatment in vitro and in vivo; rescue of palate fusion Human molecular genetics High 23975680
2014 miR-145 directly targets the 3'-UTR of TGFBR2 mRNA in vascular smooth muscle cells; miR-145 overexpression attenuates TGFβ receptor II-dependent extracellular matrix gene expression and fibrosis, while miR-145 knockout mice show increased matrix synthesis and a pronounced fibrotic response to angiotensin II; endothelial cell co-culture induces miR-143/145 expression via Notch signaling. miR-145 overexpression/knockout in cell culture and mouse models; luciferase 3'-UTR reporter assay; angiotensin II infusion; ECM gene expression analysis Circulation research High 25323858
2019 NG2 glia-derived TGF-β2 signals through TGFBR2 in microglia to maintain brain immune homeostasis; gain- and loss-of-function of NG2 glia-TGF-β2 or microglial TGFBR2 regulate CX3CR1-mediated immune suppression; ablation of NG2 glia or TGFBR2 deficiency in microglia leads to exaggerated neuroinflammation and dopaminergic neuron loss in MPTP model. Diphtheria toxin-mediated NG2 glia ablation; RNA sequencing; co-cultures of NG2 glia and microglia; gain/loss-of-function experiments for TGFβ2 and TGFBR2; MPTP mouse model; immunohistochemistry BMC medicine High 31727112
2013 miR-21 suppresses TGFBR2 expression by binding its 3'-UTR; androgen receptor (AR) signaling potentiates this effect, creating a positive feedback loop where miR-21 and AR regulate each other's expression; this miR-21/AR axis attenuates TGFβ-mediated Smad2/3 activation, cell growth inhibition, migration inhibition, and apoptosis in prostate cancer cells. 3'-UTR luciferase reporter assay; AR/miR-21 overexpression and knockdown in prostate epithelial cell lines and xenografts; Western blot for p-Smad2/3; cell growth, migration, and apoptosis assays Oncogene High 24037531
2006 TGFBR2 frameshift mutations in TGFBR2 exon 3 (polyadenine tract BAT-RII) occur at elevated rates in MLH1-deficient cells; reconstitution of TGFBR2 expression in an MSI colon cancer cell line (HCT116) decreases proliferation and reduces cdk4 expression and kinase activity, establishing that TGFBR2 inactivation drives increased cdk4-dependent proliferation in MSI colorectal cancer. TGFBR2 reconstitution in HCT116 MSI cell line; proliferation assays; cdk4 immunostaining and kinase activity assay in primary colon cancers with mutant vs. wild-type BAT-RII International journal of cancer High 16108056
2008 MLH1 deficiency produces ~11-fold higher TGFBR2 microsatellite mutation rates compared to MSH6 deficiency; TGFBR2 microsatellite mutates ~3× faster than ACVR2 in both hMLH1 and hMSH6 deficient backgrounds, establishing that TGFBR2 frameshift mutation rate is dependent on specific MMR gene background. EGFP frameshift reporter plasmids containing TGFBR2 or ACVR2 coding microsatellites in MMR-deficient cell lines; flow cytometry; DNA sequencing PloS one High 18941508
2019 Loss of Tgfbr2 in Kras-mutant lung cells promotes lung squamous cell carcinoma (SCC) formation through a Smad-independent ERK1/2 pathway; low pERK1/2 upregulates SOX2 expression (oncogenic SCC driver), and ERK1/2 suppression cooperates with SMAD4 loss to elevate SOX2; Smad4 loss alone does not drive SCC, placing ERK1/2 downstream of Tgfbr2 as a key suppressor of SOX2-driven SCC. Kras × Tgfbr2 conditional KO mouse model; Kras × Smad4 conditional KO comparison; ERK1/2 inhibitor treatment; SOX2 expression analysis; IHC of mouse and human tumors Cancer research High 31209059
2019 TGFBR2 reconstitution in MSI colorectal cancer cells alters the protein composition of secreted exosomes; TGFBR2 expression status determines a distinct exosomal proteome and modulates cytokine secretion (IL-4, SCF, PDGF-B) in recipient hepatoma cells. Doxycycline-inducible TGFBR2 reconstitution in HCT116-TGFBR2 cells; exosome isolation and mass spectrometry proteomics; nanoparticle tracking; confocal microscopy; Luminex cytokine profiling Cell communication and signaling High 28376875
2016 TGFBR2 reconstitution in HCT116 MSI colorectal cancer cells increases LFNG glycosyltransferase expression in a TGFBR2-dependent manner and enhances N-acetyl-d-glucosamine incorporation into Notch1, linking TGFBR2 signaling to Notch1 glycosylation via LFNG. Doxycycline-inducible TGFBR2 reconstitution in HCT116; Glyco-Gene Chip array; real-time RT-PCR validation; dual [³H]-GlcNAc/[³⁵S]-methionine metabolic labeling; Notch1 immunoprecipitation Cellular signalling High 27156840
2014 Neural-specific deletion of Tgfbr2 (Foxg1-Cre) impairs brain angiogenesis through an altered secretome; VEGFA, IGF1, IGF2, TGFβ, ID1, THBS2, and ADAMTS1 are altered; conditioned medium from Tgfbr2-KO neural cultures causes HUVEC branching and migration defects that are rescued by supplementing VEGFA, FGF2, and IGF1. Foxg1-Cre conditional KO of Tgfbr2; conditioned medium transfer to HUVECs; HUVEC branching and migration assays; growth factor supplementation rescue experiments; gene expression analysis Human molecular genetics High 24990151
2023 USP33, a deubiquitinating enzyme, interacts with TGFBR2 (identified by mass spectrometry and luciferase complementation), deubiquitinates TGFBR2, prevents its lysosomal degradation, and promotes its accumulation at the cell membrane to sustain TGFβ signaling; TGFβ target gene ZEB1 transcriptionally upregulates USP33, creating a positive feedback loop. Mass spectrometry interactome; luciferase complementation assay; ubiquitination assay; lysosome inhibitor experiments; ChIP for ZEB1; Western blot; functional proliferation/migration/invasion assays Cell death & disease High 37322017
2024 ITGB5 (integrin β5) promotes TGFBR2 endosomal recycling by acting as a scaffold that interacts with both TGFBR2 and the sorting nexin SNX17, preventing lysosomal degradation of TGFBR2 and maintaining its cell-surface distribution; TGFβ signaling directly upregulates ITGB5, creating a positive feedback loop that enhances TGFβ-mediated EMT and gastric cancer metastasis. Co-immunoprecipitation of ITGB5/TGFBR2/SNX17; ITGB5 knockdown in vitro and in vivo; endosomal recycling assay; Western blot for TGFBR2 surface and total levels; feedback loop validation Cancer letters High 38729557
2025 PIEZO1 attenuates TGFβ signaling by promoting endocytosis and autophagy of TGFBR2 via Rab GTPase 3C; PIEZO1 knockout in smooth muscle cells of Marfan syndrome mice exacerbates TAA and TGFβ pathway activation by inhibiting TGFBR2 endocytosis/autophagy; pharmacological PIEZO1 activation (Yoda1) prevents TGFβ activation and reverses TAA. SMC-specific PIEZO1 conditional KO in Marfan syndrome (Fbn1C1041G/+) mice; Yoda1 pharmacological treatment; Rab3C interaction experiments; endocytosis/autophagy assays; aortic histology and TGFβ pathway analysis European heart journal Medium 39585648
2021 The E3 ubiquitin ligase HUWE1 mediates ubiquitination and degradation of TGFBR2 in gastric cancer cells; HUWE1 overexpression promotes GC cell proliferation, migration, and invasion, and these effects are impaired by TGFBR2 overexpression, placing TGFBR2 downstream of HUWE1-mediated ubiquitin-proteasome degradation. HUWE1 overexpression/silencing in GC cell lines; ubiquitination assay; Western blot; MTT and Transwell assays; TGFBR2 rescue experiments Investigational new drugs Medium 33405091
2021 CRISPR/Cas9-mediated knockout of TGFBR2 in ovarian cancer tumor-infiltrating lymphocytes renders them resistant to TGFβ-mediated immunosuppression, evidenced by absence of SMAD phosphorylation, preserved proinflammatory cytokine secretion, and improved cytotoxicity in the presence of TGFβ. CRISPR/Cas9 KO of TGFBR2 in primary patient TILs; Western blot for p-SMAD; cytokine secretion assays; cytotoxicity assay; transcriptome analysis; off-target sequencing Journal for immunotherapy of cancer High 35882447
2019 TGFBR2 reconstitution in MSI colorectal cancer cells alters miRNA expression profiles in both cells and secreted extracellular vesicles; specific subsets of miRNAs are regulated in a TGFBR2-dependent manner, including downregulation of miR-381-3p in TGFBR2-deficient cells and EVs. Doxycycline-inducible TGFBR2 reconstitution in HCT116-TGFBR2; small RNA sequencing of cell and EV miRNA profiles; isogenic comparison International journal of oncology Medium 31432155
2022 The transcription factor GABPA directly activates TGFBR2 transcription (ChIP identified GABPA binding at TGFBR2 locus); GABPA and TGFBR2 phenocopy each other in suppressing renal cell carcinoma proliferation, invasion, and stemness; oncometabolite L-2-HG epigenetically silences GABPA via DNA methylation, disrupting the GABPA-TGFBR2-TGFβ axis. siRNA/overexpression of GABPA; RNA sequencing to identify TGFBR2 as GABPA target; ChIP assay for GABPA at TGFBR2 locus; L-2-HG treatment with methylation analysis; xenograft mouse model Journal of experimental & clinical cancer research High 35549739
2021 SOX4 directly activates TGFBR2 transcription; SOX4 and the SWI/SNF ATPase SMARCA4 form a complex that maintains open chromatin at TGFBR2 regulatory regions; TGFBR2 is required to mediate SOX4-dependent PI3K/Akt signaling in triple-negative breast cancer. Genomic/proteomic analyses; ChIP for SOX4/SMARCA4 at TGFBR2 locus; chromatin accessibility assay (ATAC-seq equivalent); TGFBR2 knockdown rescue of SOX4-driven PI3K signaling; Co-IP of SOX4/SMARCA4 complex NPJ breast cancer High 33837205
2017 YAP-1 promotes TGFBR2 transcription by binding directly to the TGFBR2 promoter through TEAD transcription factors in T cells, thereby promoting Treg differentiation and immunosuppression in hepatocellular carcinoma. Bioinformatics identification of YAP-1/TEAD binding sites in TGFBR2 promoter; luciferase reporter assay; ChIP/promoter binding assay; overexpression of YAP-1 in T cells; flow cytometry for Treg markers Cellular physiology and biochemistry Medium 28472799
2020 YAP/TAZ represses TGFBR2 both post-transcriptionally through the miR-106b-25 cluster and transcriptionally via EZH2 (identified as a YAP/TAZ transcriptional target); YAP/TAZ and EZH2 cooperate to repress TGFBR2 in NSCLC. miRNA target validation; EZH2 as YAP/TAZ target gene analysis; reporter assays; Western blot; correlation in clinical NSCLC samples Cancer letters Medium 33296708
2021 MYOCD localizes to the TGFBR2 promoter region and recruits PRMT5/MEP50 complex to epigenetically silence TGFBR2 transcription; loss of MYOCD leads to TGFBR2 hyperactivation, and NSCLC cells deficient in MYOCD are particularly sensitive to TGFBR kinase inhibitors. ChIP showing MYOCD at TGFBR2 promoter; PRMT5/MEP50 co-recruitment assay; TGFBR2 expression analysis with MYOCD manipulation; sensitivity assays with TGFBRi Theranostics Medium 33995678
2019 TGFβ signaling through SMAD2/3 transcriptionally induces miR-520e expression (confirmed by ChIP-PCR), which in turn targets and downregulates TGFBR2, constituting a TGFβ-SMAD-miR-520e-TGFBR2 negative-feedback loop in NSCLC cells. ChIP-PCR for SMAD2/3 at miR-520e promoter; miR-520e overexpression/inhibition; luciferase 3'-UTR reporter for TGFBR2; Western blot; clinical correlation in NSCLC samples Carcinogenesis Medium 30475986
2019 GDF15-induced apoptosis, caspase-9/3 activation, and ERK1/2/p38 MAPK inhibition in A549 cells depends on TGFBR2 expression; TGFBR2 silencing blocks all GDF15-induced apoptotic and MAPK effects, placing TGFBR2 as a required mediator of GDF15 signaling in this cell context. GDF15 overexpression (full and mature forms); siRNA knockdown of TGFBR2; flow cytometry for annexin V/PI; caspase activity assays; ERK1/2 and p38 phosphorylation by Western blot Cell biochemistry and function Medium 31172564
2023 NRP1 (neuropilin-1) interacts with TGFBR2 at endothelial adherens junctions (Co-IP), reduces plasma membrane localization of TGFBR2, and suppresses TGFβ signaling; NRP1 knockdown increases TGFBR2 membrane abundance and TGFβ-driven inflammation. Co-IP of NRP1 with TGFBR2; NRP1 endothelial-specific KO mice; surface TGFBR2 localization analysis; inflammatory marker expression; atherosclerosis model Science signaling High 37220183
2019 A super-enhancer (marked by H3K27Ac) at the TGFBR2 locus controls its transcription in pancreatic cancer cells; CRISPR deletion of this super-enhancer (sgTGFBR2-SEΔ) reduces TGFBR2 expression, impairs TGFβ-induced p-SMAD2/3 signaling, and attenuates TGFβ-induced migration and EMT. H3K27Ac ChIP-seq; BRD4 inhibitor (JQ1) treatment; CRISPR sgRNA-mediated super-enhancer deletion; p-SMAD2/3 Western blot; migration and EMT assays Cellular signalling Medium 31730895
2021 Enzalutamide decreases TGFBR2 protein expression in osteoblasts through PTH1R-mediated endocytosis; PTH1R blockade rescues enzalutamide-mediated TGFBR2 reduction and restores enzalutamide sensitivity in prostate cancer cells co-cultured with osteoblasts. Co-culture of PCa cells with osteoblasts; PTH1R inhibitor rescue; Western blot for TGFBR2 protein; bone metastasis mouse models; clinical data analysis Cancer letters Medium 34752846
2022 TGFBR2 reconstitution in MSI/MMR-deficient VCMsh2/Tgfbr2 mice modulates gut microbiota composition; combined loss of Msh2 and Tgfbr2 in intestinal epithelium synergistically promotes inflammation-associated colorectal cancer, and gut microbiota strongly modulates tumor incidence. Villin-Cre dual conditional KO of Msh2 and Tgfbr2; intestinal tumor analysis; mutational spectra; gene expression profiling; microbiota compositional analysis Cellular and molecular gastroenterology and hepatology Medium 35688320
2016 Tgfbr2 deletion in Osx-Cre-expressing immature osteoblasts causes postnatal reduction in bone volume due to decreased osteoblast proliferation (PCNA reduction) and impaired maturation (Bglap/osteocalcin mRNA reduced) without altering Runx2 mRNA or apoptosis. Osx-Cre conditional KO; microCT; histomorphometry; qRT-PCR for Runx2, Bglap, PCNA, Bax/Bcl2; osteoblast and osteoclast enumeration Bone Medium 28043895
2015 Odontoblast-specific loss of Tgfbr2 disrupts odontoblast polarity and matrix secretion after mantle dentin formation, reduces alkaline phosphatase and Dsp expression, increases Dmp1, and causes ectopic fibrous matrix calcification leading to pulpal obliteration. Odontoblast-specific Cre conditional KO; immunohistochemistry for ALP, Dsp, Dmp1, collagen I, biglycan; microCT Journal of dental research Medium 25818583
2019 A TGFBR2/SMAD2/DNMT1/miR-145 negative regulatory loop operates in LPS-induced sepsis: miR-145 directly targets TGFBR2 (confirmed by luciferase reporter and RIP); activated SMAD2 binds the DNMT1 promoter (ChIP), upregulating DNMT1 which methylates the miR-145 promoter, suppressing miR-145 and further increasing TGFBR2 expression. Luciferase reporter; ChIP for SMAD2 at DNMT1 promoter; RIP assay; miR-145 promoter methylation; TGFBR2 knockdown; LPS sepsis mouse model Biomedicine & pharmacotherapy Medium 30784922
2020 TGFBR2 interacts with PDGFR in GBM cells (Co-immunoprecipitation); concurrent TGFBR2 and PDGFR expression attenuates PDGFRi toxicity and maintains downstream PDGFR signaling under inhibitor treatment, contributing to PDGFRi resistance. Co-immunoprecipitation of TGFBR2 with PDGFR in GBM cells; PDGFRi toxicity assays; PDGFR downstream signaling Western blot American journal of cancer research Medium 29888103
2020 Hypoxia-induced EZH2 promotes H3K27me3 at the TGFBR2 promoter, causing hypermethylation and epigenetic silencing of TGFBR2 in prostate cancer; separately, hypoxia upregulates miR-93 which also targets and suppresses TGFBR2. EZH2 siRNA/inhibitor experiments; methylation-specific PCR; ChIP for H3K27me3 at TGFBR2 promoter; luciferase 3'-UTR reporter for miR-93/TGFBR2; demethylation agent rescue Journal of experimental & clinical cancer research Medium 29699590
2017 Combined mutation of Apc, Kras, and Tgfbr2 deletion in intestinal epithelial cells cooperates to drive colorectal cancer metastasis; Tgfbr2 deletion combined with Kras mutation induces EMT-like morphology and lymph vessel intravasation; liver metastasis requires Kras combined with either Trp53 or Tgfbr2 deletion, with highest metastasis in the Apc/Kras/Tgfbr2 combination. Intestinal epithelial conditional KO mouse models with combinations of Apc, Kras, Tgfbr2, Trp53, Fbxw7; tumor-derived organoid splenic transplantation metastasis assay; RNA sequencing Cancer research High 29282223

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2005 A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nature genetics 1295 15731757
2004 Heterozygous TGFBR2 mutations in Marfan syndrome. Nature genetics 468 15235604
2014 Tgfbr2 disruption in postnatal smooth muscle impairs aortic wall homeostasis. The Journal of clinical investigation 247 24401272
2007 ALK5- and TGFBR2-independent role of ALK1 in the pathogenesis of hereditary hemorrhagic telangiectasia type 2. Blood 186 17911384
2009 Analysis of multigenerational families with thoracic aortic aneurysms and dissections due to TGFBR1 or TGFBR2 mutations. Journal of medical genetics 146 19542084
2006 TGFBR1 and TGFBR2 mutations in patients with features of Marfan syndrome and Loeys-Dietz syndrome. Human mutation 144 16799921
2006 Cell autonomous requirement for Tgfbr2 in the disappearance of medial edge epithelium during palatal fusion. Developmental biology 124 16780827
2013 Androgen receptor and microRNA-21 axis downregulates transforming growth factor beta receptor II (TGFBR2) expression in prostate cancer. Oncogene 118 24037531
2019 NG2 glia regulate brain innate immunity via TGF-β2/TGFBR2 axis. BMC medicine 116 31727112
2017 Combined Mutation of Apc, Kras, and Tgfbr2 Effectively Drives Metastasis of Intestinal Cancer. Cancer research 114 29282223
2010 TGFBR2 mutations alter smooth muscle cell phenotype and predispose to thoracic aortic aneurysms and dissections. Cardiovascular research 109 20628007
2018 The CDR1as/miR-7/TGFBR2 Axis Modulates EMT in Silica-Induced Pulmonary Fibrosis. Toxicological sciences : an official journal of the Society of Toxicology 100 30202956
2017 MiR-9-5p promotes cell growth and metastasis in non-small cell lung cancer through the repression of TGFBR2. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 89 29239816
2018 Linc00462 promotes pancreatic cancer invasiveness through the miR-665/TGFBR1-TGFBR2/SMAD2/3 pathway. Cell death & disease 87 29899418
2006 Identification and in silico analyses of novel TGFBR1 and TGFBR2 mutations in Marfan syndrome-related disorders. Human mutation 85 16791849
2020 YAP/TAZ and EZH2 synergize to impair tumor suppressor activity of TGFBR2 in non-small cell lung cancer. Cancer letters 76 33296708
2014 MicroRNA miR145 regulates TGFBR2 expression and matrix synthesis in vascular smooth muscle cells. Circulation research 76 25323858
2014 MicroRNA-301a promotes migration and invasion by targeting TGFBR2 in human colorectal cancer. Journal of experimental & clinical cancer research : CR 70 25551793
2016 Dual targeting of ANGPT1 and TGFBR2 genes by miR-204 controls angiogenesis in breast cancer. Scientific reports 63 27703260
2013 Inactivation of Tgfbr2 in Osterix-Cre expressing dental mesenchyme disrupts molar root formation. Developmental biology 63 23933490
2010 Quantitative analysis of TGFBR2 mutations in Marfan-syndrome-related disorders suggests a correlation between phenotypic severity and Smad signaling activity. Journal of cell science 57 21098638
2019 MiR-145 negatively regulates TGFBR2 signaling responsible for sepsis-induced acute lung injury. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 54 30841464
2017 miRNA-520f Reverses Epithelial-to-Mesenchymal Transition by Targeting ADAM9 and TGFBR2. Cancer research 54 28209612
2006 Tgfbr2 regulates the maintenance of boundaries in the axial skeleton. Developmental biology 51 16824508
2020 miR-20a-5p/TGFBR2 Axis Affects Pro-inflammatory Macrophages and Aggravates Liver Fibrosis. Frontiers in oncology 49 32117757
2006 Two novel and one known mutation of the TGFBR2 gene in Marfan syndrome not associated with FBN1 gene defects. European journal of human genetics : EJHG 49 16251899
2017 YAP-1 Promotes Tregs Differentiation in Hepatocellular Carcinoma by Enhancing TGFBR2 Transcription. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 48 28472799
2015 miR-135b Promotes Cancer Progression by Targeting Transforming Growth Factor Beta Receptor II (TGFBR2) in Colorectal Cancer. PloS one 48 26061281
2007 Severe aortic and arterial aneurysms associated with a TGFBR2 mutation. Nature clinical practice. Cardiovascular medicine 48 17330129
2009 Tgfbr2 is required for development of the skull vault. Developmental biology 47 19699732
2018 Lnc-SNHG1 Activates the TGFBR2/SMAD3 and RAB11A/Wnt/β-Catenin Pathway by Sponging MiR-302/372/373/520 in Invasive Pituitary Tumors. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 43 30048990
2012 MicroRNA-337 is associated with chondrogenesis through regulating TGFBR2 expression. Osteoarthritis and cartilage 43 22425884
2020 Circular RNA TGFBR2 acts as a ceRNA to suppress nasopharyngeal carcinoma progression by sponging miR-107. Cancer letters 42 33160003
2007 TGFB1 and TGFBR2 functional polymorphisms and risk of esophageal squamous cell carcinoma: a case-control analysis in a Chinese population. Journal of cancer research and clinical oncology 38 17680270
2022 CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signaling. Journal for immunotherapy of cancer 37 35882447
2020 LncRNA MIR4435-2HG potentiates the proliferation and invasion of glioblastoma cells via modulating miR-1224-5p/TGFBR2 axis. Journal of cellular and molecular medicine 36 32319715
2018 ERBB3, IGF1R, and TGFBR2 expression correlate with PDGFR expression in glioblastoma and participate in PDGFR inhibitor resistance of glioblastoma cells. American journal of cancer research 36 29888103
2008 Absence of TGFBR1 and TGFBR2 mutations in patients with bicuspid aortic valve and aortic dilation. The American journal of cardiology 36 18721526
2015 The anti-fibrotic effects of microRNA-153 by targeting TGFBR-2 in pulmonary fibrosis. Experimental and molecular pathology 35 26216407
2020 Circular RNA FOXO3 Suppresses Bladder Cancer Progression and Metastasis by Regulating MiR-9-5p/TGFBR2. Cancer management and research 34 32612392
2018 Attenuation of TGFBR2 expression and tumour progression in prostate cancer involve diverse hypoxia-regulated pathways. Journal of experimental & clinical cancer research : CR 34 29699590
2016 miR-373 Inhibits Glioma Cell U251 Migration and Invasion by Down-Regulating CD44 and TGFBR2. Cellular and molecular neurobiology 34 26858153
2018 A Neutralizing Aptamer to TGFBR2 and miR-145 Antagonism Rescue Cigarette Smoke- and TGF-β-Mediated CFTR Expression. Molecular therapy : the journal of the American Society of Gene Therapy 33 30595527
2014 Neural deletion of Tgfbr2 impairs angiogenesis through an altered secretome. Human molecular genetics 33 24990151
2019 LncRNA PART-1 targets TGFBR2/Smad3 to regulate cell viability and apoptosis of chondrocytes via acting as miR-590-3p sponge in osteoarthritis. Journal of cellular and molecular medicine 32 31571401
2017 TGFBR2-dependent alterations of exosomal cargo and functions in DNA mismatch repair-deficient HCT116 colorectal cancer cells. Cell communication and signaling : CCS 32 28376875
2019 A TGFBR2/SMAD2/DNMT1/miR-145 negative regulatory loop is responsible for LPS-induced sepsis. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 30 30784922
2019 GDF15 induced apoptosis and cytotoxicity in A549 cells depends on TGFBR2 expression. Cell biochemistry and function 30 31172564
2019 A super-enhancer controls TGF- β signaling in pancreatic cancer through downregulation of TGFBR2. Cellular signalling 29 31730895
2006 Proliferation and Cdk4 expression in microsatellite unstable colon cancers with TGFBR2 mutations. International journal of cancer 29 16108056
2019 Dysregulated Tgfbr2/ERK-Smad4/SOX2 Signaling Promotes Lung Squamous Cell Carcinoma Formation. Cancer research 28 31209059
2014 MicroRNA-200b stimulates tumour growth in TGFBR2-null colorectal cancers by negatively regulating p27/kip1. Journal of cellular physiology 28 24151081
2023 USP33 promotes pancreatic cancer malignant phenotype through the regulation of TGFBR2/TGFβ signaling pathway. Cell death & disease 27 37322017
2020 Antisense Oligonucleotide in LNA-Gapmer Design Targeting TGFBR2-A Key Single Gene Target for Safe and Effective Inhibition of TGFβ Signaling. International journal of molecular sciences 27 32178467
2013 Modulation of lipid metabolic defects rescues cleft palate in Tgfbr2 mutant mice. Human molecular genetics 27 23975680
2017 1,25(OH)2D3 attenuates pulmonary arterial hypertension via microRNA-204 mediated Tgfbr2/Smad signaling. Experimental cell research 25 29196166
2016 MicroRNA-302d downregulates TGFBR2 expression and promotes hepatocellular carcinoma growth and invasion. Experimental and therapeutic medicine 25 28352351
2022 GABPA-activated TGFBR2 transcription inhibits aggressiveness but is epigenetically erased by oncometabolites in renal cell carcinoma. Journal of experimental & clinical cancer research : CR 24 35549739
2008 A new locus-specific database (LSDB) for mutations in the TGFBR2 gene: UMD-TGFBR2. Human mutation 24 17935258
2021 TGFBR2 mutation predicts resistance to immune checkpoint inhibitors in patients with non-small cell lung cancer. Therapeutic advances in medical oncology 23 34408796
2012 TGFBR2 but not SPP1 genotype modulates osteopontin expression in Duchenne muscular dystrophy muscle. The Journal of pathology 23 22431140
2022 Decrease of circARID1A retards glioblastoma invasion by modulating miR-370-3p/ TGFBR2 pathway. International journal of biological sciences 22 35982888
2020 CircRNA TGFBR2/MiR-25-3p/TWIST1 axis regulates osteoblast differentiation of human aortic valve interstitial cells. Journal of bone and mineral metabolism 22 33070258
2008 Mutation rates of TGFBR2 and ACVR2 coding microsatellites in human cells with defective DNA mismatch repair. PloS one 22 18941508
2021 SOX4 and SMARCA4 cooperatively regulate PI3k signaling through transcriptional activation of TGFBR2. NPJ breast cancer 21 33837205
2019 MicroRNA-3191 promotes migration and invasion by downregulating TGFBR2 in colorectal cancer. Journal of biochemical and molecular toxicology 21 30770602
2023 Neuropilin-1 interacts with VE-cadherin and TGFBR2 to stabilize adherens junctions and prevent activation of endothelium under flow. Science signaling 20 37220183
2020 CircSERPINE2 weakens IL-1β-caused apoptosis and extracellular matrix degradation of chondrocytes by regulating miR-495/TGFBR2 axis. Bioscience reports 20 33094798
2016 Tgfbr2 is required in osterix expressing cells for postnatal skeletal development. Bone 20 28043895
2015 Disruption of Tgfbr2 in odontoblasts leads to aberrant pulp calcification. Journal of dental research 19 25818583
2011 Mutations in TGFBR2 gene cause spontaneous cervical artery dissection. Journal of neurology, neurosurgery, and psychiatry 19 21270064
2011 Association between TGFBR2 gene polymorphism (rs2228048, Asn389Asn) and intracerebral hemorrhage in Korean population. Immunological investigations 19 21609163
2025 PIEZO1 attenuates Marfan syndrome aneurysm development through TGF-β signaling pathway inhibition via TGFBR2. European heart journal 18 39585648
2022 A novel circ_MACF1/miR-942-5p/TGFBR2 axis regulates the functional behaviors and drug sensitivity in gefitinib-resistant non-small cell lung cancer cells. BMC pulmonary medicine 18 34996416
2017 Role of TGFBR1 and TGFBR2 genetic variants in Marfan syndrome. Journal of vascular surgery 18 28847661
2021 Targeting hyperactive TGFBR2 for treating MYOCD deficient lung cancer. Theranostics 17 33995678
2020 Propofol Inhibits Cell Proliferation, Migration, and Invasion via mir-410-3p/Transforming Growth Factor-β Receptor Type 2 (TGFBR2) Axis in Glioma. Medical science monitor : international medical journal of experimental and clinical research 17 31960827
2009 A new sporadic case of early-onset Loeys-Dietz syndrome due to the recurrent mutation p.R528C in the TGFBR2 gene substantiates interindividual clinical variability. Journal of applied genetics 17 19875893
2021 miR-128-3p inhibits apoptosis and inflammation in LPS-induced sepsis by targeting TGFBR2. Open medicine (Warsaw, Poland) 16 33623823
2021 FGD5-AS1 Inhibits Osteoarthritis Development by Modulating miR-302d-3p/TGFBR2 Axis. Cartilage 16 33834880
2021 circ_TGFBR2 Inhibits Vascular Smooth Muscle Cells Phenotypic Switch and Suppresses Aortic Dissection Progression by Sponging miR-29a. Journal of inflammation research 16 34795497
2019 TGFBR2‑dependent alterations of microRNA profiles in extracellular vesicles and parental colorectal cancer cells. International journal of oncology 16 31432155
2024 ITGB5 facilitates gastric cancer metastasis by promoting TGFBR2 endosomal recycling. Cancer letters 15 38729557
2023 Exosomes from adipose-derived mesenchymal stem cells improve liver fibrosis by regulating the miR-20a-5p/TGFBR2 axis to affect the p38 MAPK/NF-κB pathway. Cytokine 15 37852157
2021 LINC00052 promotes breast cancer cell progression and metastasis by sponging miR-145-5p to modulate TGFBR2 expression. Oncology letters 15 33777194
2021 Enzalutamide-induced and PTH1R-mediated TGFBR2 degradation in osteoblasts confers resistance in prostate cancer bone metastases. Cancer letters 15 34752846
2019 TGF-β-SMAD-miR-520e axis regulates NSCLC metastasis through a TGFBR2-mediated negative-feedback loop. Carcinogenesis 15 30475986
2016 Reconstitution of TGFBR2 in HCT116 colorectal cancer cells causes increased LFNG expression and enhanced N-acetyl-d-glucosamine incorporation into Notch1. Cellular signalling 15 27156840
2013 Dural ectasia in Loeys-Dietz syndrome: comprehensive study of 30 patients with a TGFBR1 or TGFBR2 mutation. Clinical genetics 15 24344637
2022 Transforming Growth Factor Beta Receptor 2 (TGFBR2) Promoter Region Polymorphisms May Be Involved in Mandibular Retrognathism. BioMed research international 14 35757474
2022 GDF15 negatively regulates chemosensitivity via TGFBR2-AKT pathway-dependent metabolism in esophageal squamous cell carcinoma. Frontiers of medicine 14 36525138
2021 Circ_0001686 Promotes Prostate Cancer Progression by Up-Regulating SMAD3/TGFBR2 via miR-411-5p. The world journal of men's health 14 34169675
2021 CircSEC24A upregulates TGFBR2 expression to accelerate pancreatic cancer proliferation and migration via sponging to miR-606. Cancer cell international 14 34906151
2012 TGFBR2 gene polymorphism is associated with ossification of the posterior longitudinal ligament. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 14 23228659
2020 TGFBR2 Regulates Hedgehog Pathway and Cervical Cancer Cell Proliferation and Migration by Mediating SMAD4. Journal of proteome research 13 32628850
2021 The E3 ligase HUWE1 mediates TGFBR2 ubiquitination and promotes gastric cancer cell proliferation, migration, and invasion. Investigational new drugs 12 33405091
2021 Long non-coding RNA CDKN2B-AS1 enhances LPS-induced apoptotic and inflammatory damages in human lung epithelial cells via regulating the miR-140-5p/TGFBR2/Smad3 signal network. BMC pulmonary medicine 12 34126975
2015 TGFβ-1 and TGFBR2 polymorphisms, cooking oil fume exposure and risk of lung adenocarcinoma in Chinese nonsmoking females: a case control study. BMC medical genetics 12 25928368
2023 Dysregulation of the circ_0087502/miR-1179/TGFBR2 pathway supports gemcitabine resistance in pancreatic cancer. Cancer biology & therapy 11 37844011
2022 Loss of MMR and TGFBR2 Increases the Susceptibility to Microbiota-Dependent Inflammation-Associated Colon Cancer. Cellular and molecular gastroenterology and hepatology 11 35688320

Missed literature

Know a paper Affinage missed for TGFBR2? Flag it for the maintainers and the community.

No submissions yet.